Celldex Therapeutics, Inc. (CLDX): Earnings News

CLDX – Reports Q4 EPS loss of $0.03. Beats on revenues.


Key Facts Surrounding This News Item


  • CLDX had a POWR Rating of D (Sell) coming into today.
  • CLDX was 2.16% above its 10-Day Moving Average coming into today.
  • CLDX was 1.69% above its 20-Day Moving Average coming into today.
  • CLDX was -9.07% below its 50-Day Moving Average coming into today.
  • CLDX was -11.84% below its 100-Day Moving Average coming into today.
  • CLDX was -9.29% below its 200-Day Moving Average coming into today.
  • CLDX had returned -15.14% year-to-date leading up to today’s news, versus a +2.26% return from the benchmark S&P 500 during the same period.

More Info About Celldex Therapeutics, Inc. (CLDX)


Celldex Therapeutics is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The company was founded in 2004 and is based in Hampton, New Jersey. View our full CLDX ticker page with ratings, news, and more.

CLDX at a Glance

CLDX Current POWR Rating™
Overall POWR Rating™
CLDX Current Price $0.26 1.16%
More CLDX Ratings, Data, and News

CLDX Price Reaction

The day of this event (Mar. 7, 2018)
CLDX Closing Price$2.47 2.49%
CLDX Volume1,530,100
0.24% from avg
Leading up to this event
CLDX 1-mo return4.74%
After this event
CLDX 1-day return12.36%
CLDX 3-day return14.54%
CLDX 5-day return5.49%

CLDX Price Chart


The Top Stocks For 2019

More Celldex Therapeutics, Inc. (CLDX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CLDX News
Page generated in 0.9719 seconds.